Drug intelligence / Profile preview

PRBT001

Development stage: Preclinical
Lead developer: PanRu Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

PRBT001 is a preclinical, novel mRNA therapeutic cancer vaccine for prostate cancer that uses a three‑component lipid nanoparticle (LNP) delivery system licensed by CanSino Biologics from Panru Biotech. It is designed to deliver mRNA encoding tumor‑associated antigens to elicit a targeted antitumor immune response, leveraging LNP technology with completely independent intellectual property to improve systemic delivery and immunogenicity in prostate cancer settings.[9][15]

Beyond the preview

Go deeper on PRBT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRBT001.

Explore the full profile